Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Swedish Orphan Biovitrum    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM (SOBI)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
08/14/2018 08/15/2018 08/16/2018 08/17/2018 08/20/2018 Date
259.3(c) 258.1(c) 264(c) 266(c) 268.2 Last
822 921 460 817 557 642 781 782 1 004 617 Volume
-0.04% -0.46% +2.29% +0.76% +0.83% Change
More quotes
Financials (SEK)
Sales 2018 9 101 M
EBIT 2018 3 287 M
Net income 2018 2 582 M
Finance 2018 3 367 M
Yield 2018 -
Sales 2019 10 645 M
EBIT 2019 4 053 M
Net income 2019 3 177 M
Finance 2019 5 443 M
Yield 2019 -
P/E ratio 2018 27,89
P/E ratio 2019 22,63
EV / Sales2018 7,60x
EV / Sales2019 6,30x
Capitalization 72 487 M
More Financials
Company
Swedish Orphan Biovitrum AB engages as a biopharmaceutical company.It provides therapies and services for patients with rare diseases.The firm's core products include Kineret within the inflammation therapeutic area; and Orfadin, Ammonaps, and Ammonul within the genetics and metabolic therapeutic... 
Sector
Pharmaceuticals
Calendar
10/31Earnings Release
More about the company
Surperformance© ratings of Swedish Orphan Biovitrum
Trading Rating : Investor Rating :
More Ratings
Latest news on SWEDISH ORPHAN BIOVITRUM
08/17SWEDISH ORPHAN BIOVITRUM : First patient dosed in phase 1/2 study evaluating SOB..
AQ
08/16SWEDISH ORPHAN BIOVITRUM : First Patient Dosed in Phase 1/2 Study Evaluating SOB..
AQ
08/10SWEDISH ORPHAN BIOVITRUM : First patient dosed in phase 1/2 study evaluating SOB..
AQ
08/01SOBI : Names Jeff Henderson Vice President, Head of Market Access and Government..
BU
07/24SWEDISH ORPHAN BIOVITRUM : Sobi strengthens inflammation franchise by acquiring ..
AQ
07/20SWEDISH ORPHAN BIOVITRUM : Sobi™ strengthens inflammation franchise by acq..
AQ
07/18SWEDISH ORPHAN BIOVITRUM AB (PUBL) : Swedish Orphan Biovitrum AB to Host Earning..
AC
07/18SWEDISH ORPHAN BIOVITRUM : The Board of directors exercises authorisation for re..
PU
07/18SWEDISH ORPHAN BIOVITRUM : The Board of directors exercises authorisation for re..
AQ
07/18SWEDISH ORPHAN BIOVITRUM : Sobi™ publishes the report for the second quart..
AQ
More news
Sector news : Pharmaceuticals - NEC
08:27aROCHE : Alecensa latest beneficiary of faster China drug approvals
RE
07:30aRoche's Alecensa Gets Green Light From China National Drug Administration
DJ
08/18ASTRAZENECA : Biopharma Spinout Entasis Files for IPO
DJ
08/17BAYER : Rejects Media Report of Fresh Dicamba Lawsuits
DJ
08/17Bayer says dicamba report not new
RE
More sector news : Pharmaceuticals - NEC
Latest Tweets
07/20Jefferies Financial Group Raises SWEDISH ORPHAN/S Q3 2018 Earnings Estimates .. 
07/18$SOBI Orphan Biovitrum AB Sobi’s hemophilia drugs are launching in Europe, b.. 
07/18Swedish Orphan Biovitrum : The Board of directors exercises authorisation for.. 
05/09Bulletin from Swedish Orphan Biovitrum’s (publ) (“Sobi’s”) Annual General Mee.. 
04/30Jefferies Group Raises Swedish Orphan Biovitrum Q2 2018 Earnings Estimates to.. 
More tweets
Qtime:23
News from SeekingAlpha
07/24STOXX 600 Earnings Roundup - Week Of July 20, 2018 
07/18Swedish Orphan Biovitrum AB ADR 2018 Q2 - Results - Earnings Call Slides 
02/23Swedish Orphan Biovitrum AB ADR 2017 Q4 - Results - Earnings Call Slides 
02/23European advisory group backs expanded use for Swedish Orphan's Kineret 
01/23FDA signs off on Swedish Orphan's IND for MPS IIIA candidate SOBI003 
Chart SWEDISH ORPHAN BIOVITRUM
Duration : Period :
Swedish Orphan Biovitrum Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SWEDISH ORPHAN BIOVITRUM
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 203  SEK
Spread / Average Target -24%
EPS Revisions
Managers
NameTitle
Guido Oelkers President & Chief Executive Officer
Sven Håkan Björklund Chairman
Mats-Olof Wallin Chief Financial Officer & Senior Vice President
Milan Zdravkovic Chief Medical Officer, Head-Research & Development
Kristina Sjoblom Nygren Head-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
SWEDISH ORPHAN BIOVITRUM136.87%7 921
JOHNSON & JOHNSON-3.76%360 750
PFIZER16.21%246 736
NOVARTIS0.10%211 093
ROCHE HOLDING LTD.-2.66%208 211
MERCK AND COMPANY22.73%183 667